These payers demonstrate greater flexibility in coverage decisions and faster adoption of new obesity pharmacotherapy compared to public health systems with formal health technology assessment requirements
doi: 10.1016/j.isci.2024.109784 Roland BC, Lee D, Miller LS, Vegesna A, Yolken R, Severance E, et al
This early benefit helps with compliance because feeling better makes it easier to stick with the broader protocol
A study published in August 2024 found a higher risk of NAION among patients prescribed semaglutide compared to individuals using non-GLP-1 receptor agonist medications, with 17 cases occurring in the semaglutide group versus six in the comparison group
Weight loss with liraglutide is usually less than that seen with semaglutide
By looking at these pieces together, providers can tell whether progress is happening at a pace that makes sense for you